Day: September 1, 2024

PickleJar Entertainment Group, Inc. PickleJar Contest – Jackson Dean at Red Rocks HOUSTON, Sept. 01, 2024 (GLOBE NEWSWIRE) — PickleJar Entertainment Group, (OTCMKTS: PKLE), a leading Texas-based music and entertainment software company, announced today the launch of a nationwide flyaway contest with Cumulus Media and sponsored by Big Machine Records. From September 1, 2024 through September 16, 2024, PickleJar Fans will have a chance to win the Grand Prize for a winner and their guest to see Jackson Dean make his debut appearance at the legendary Red Rocks Amphitheater in Morrison, Colorado on October 12, 2024. “Jackson Dean has been a friend of the show from the very start. What better way to celebrate his Red Rocks debut by sending two lucky listeners to Colorado to share in the experience!” said Patrick Thomas,...

GUARD-AF trial results presented at European Society of Cardiology (ESC) Congress 2024 Leveraging iRhythm’s Zio® patch-based long-term continuous monitoring (LTCM), GUARD-AF is the largest randomized trial in a primary care setting to evaluate the impact of screening for undiagnosed atrial fibrillation (AF) Screening with iRhythm’s Zio® XT1 LTCM led to increase in new diagnosis of AF (5.0% vs 3.3%) over an average follow-up of 15 months. No difference in stroke hospitalization vs usual care in the context of reduced statistical power due to truncated enrollment and follow-up. SAN FRANCISCO, Sept. 01, 2024 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the presentation and publication...

Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt disease SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its board of directors has appointed Hendrik P. N. Scholl, MD, MA, as the Chief Medical Officer of the Company, effective immediately. Dr. Scholl is the foremost globally recognized authority on Stargardt disease and age-related macular degeneration (AMD), bringing decades of expertise in treating retinal diseases, including the two key indications...

NIO delivered 20,176 vehicles in August 2024 NIO delivered 128,100 vehicles year-to-date in 2024, increasing by 35.8% year-over-year Cumulative deliveries of NIO vehicles reached 577,694 as of August 31, 2024 SHANGHAI, Sept. 01, 2024 (GLOBE NEWSWIRE) — NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced its August 2024 delivery results. NIO delivered 20,176 vehicles in August 2024. The deliveries consisted of 11,923 premium smart electric SUVs, and 8,253 premium smart electric sedans. Cumulative deliveries of NIO vehicles reached 577,694 as of August 31, 2024. About NIO Inc. NIO Inc. is a pioneer and a leading company in the global smart electric vehicle market. Founded in November 2014, NIO aspires to shape a sustainable...

14,036 vehicles delivered in August 2024, a 3% increase year-over-year and up 26% over the prior month GUANGZHOU, China, Sept. 01, 2024 (GLOBE NEWSWIRE) — XPeng Inc. (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announced its vehicle delivery results for August 2024. XPENG delivered 14,036 Smart EVs in August, representing increases of 3% year-over-year and 26% over the prior month. In the first eight months of 2024, XPENG delivered 77,209 Smart EVs, a 17% increase from the same period last year. On August 27, 2024, XPENG held its 10th Anniversary Gala Night along with the official market launch of MONA M03, an intelligent all-electric hatchback coupe with three versions at prices ranging between RMB119,800 and RMB155,800, in China. With its Max version...

 Data from Integrated Safety Analysis Across Three Clinical TrialsReinforces Robust Safety Profile of Aficamten Analysis from FOREST-HCM Demonstrates Successful Withdrawal of Standard of Care Medications in Patients with Obstructive HCM Treated with Aficamten Company to Host Conference Call and Webcast Tuesday, September 3rd at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., Sept. 01, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data related to the safety and long-term use of aficamten were presented in a Late Breaking Clinical Trial presentation and oral presentation at the European Society of Cardiology Congress 2024 in London, UK. The presentations included an integrated safety analysis from three clinical studies of aficamten and an analysis of the withdrawal of standard of care...

Additional Data from SEQUOIA-HCM Demonstrate Favorable Cardiac Remodelingby Cardiac MRI, Improvements in Cardiac Structure and Function by Echocardiography,Symptom Relief and Improvement in Biomarkers with Aficamten Presentations Accompanied by Four Simultaneous Journal Publications Company to Host Conference Call and Webcast Tuesday, September 3rd at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., Sept. 01, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), related to cardiac remodeling and improvements in patient symptoms, cardiac structure,...

BEIJING, China, Sept. 01, 2024 (GLOBE NEWSWIRE) — Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced that it delivered 48,122 vehicles in August 2024, an increase of 37.8% year over year. This brought the Company’s total deliveries in 2024 to 288,103. As of August 31, 2024, its cumulative deliveries reached 921,467 vehicles. “Li L6 has gained widespread popularity among young users, with deliveries exceeding 20,000 for the third consecutive month, further expanding our market share. Notably, our share of the RMB200,000 and higher NEV market grew to 18% in July, outpacing Tesla to become the sales champion among NEV brands in China. We maintained our strong momentum, retaining the top spot in sales among China’s emerging new energy auto brands in August....